ArticleInternal medicine (Tokyo, Japan)2018

Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Akira Yokoyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.